Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Antibody drug's ability to select breast cancer patients for therapy reported
June 16th, 2005
ViroLogic, Inc., (VLGC) announced the presentation of clinical data demonstrating the ability of the company's eTag assays to accurately predict treatment response for patients with breast cancer who receive Herceptin (trastuzumab). The presentation took place at the 2005 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida. ViroLogic has developed a set of eTag assays that enables broader analysis of the human epidermal growth factor receptor (HER) family than just HER2/neu, the target for the antibody drug Herceptin, and uniquely permits measurement of "activated" HER receptors in fixed patient tumor samples. Breast...
Source: Women's Health Weekly (2005-06-16)
|
